GO
Loading...

Actavis Inc

More

  • *To pay $95/ share in cash, $30/ share in milestone payment. April 28- Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion, including milestone payments, to add a promising treatment for irritable bowel syndrome to its gastrointestinal drugs portfolio.

  • STOCKHOLM, April 28- Swedish drugmaker Meda rejected an improved takeover offer from U.S. generics firm Mylan which one person familiar with the matter said valued Meda at around $9 billion including debt, driving its shares sharply back down.

  • Early movers: CMCSA, PFE, AZN, GE & more Monday, 28 Apr 2014 | 8:02 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Forest Labs to buy Furiex Pharma for up to $1.46 bln Monday, 28 Apr 2014 | 7:38 AM ET

    April 28- Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion including milestone payments to access Furiex's treatment for irritable bowel syndrome. Forest, which itself is being acquired by Actavis Plc, said Actavis supported the deal announced on Monday.

  • With the market in the thick of earnings, next week promises to be an eventful five days for investors. Are you ready? Cramer sure is.

  • April 22- At any given time, the acquisitive chief executive of Valeant Pharmaceuticals Inc is brokering multiple deal discussions and eyeing as many as 50 buying opportunities. Pearson's latest target, with help from activist investor Bill Ackman, is Allergan Inc, maker of anti-wrinkle treatment Botox.

  • Pfizer-AstraZeneca deal? Not as crazy as it sounds Monday, 21 Apr 2014 | 6:24 PM ET
    Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc.

    There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.

  • April 17- Teva Pharmaceutical Industries Ltd signed a deal that allows the Israeli drugmaker to launch a generic version of Pfizer Inc's blockbuster painkiller Celebrex in December. "helps them to get through 2014 with a lot less competition," Morningstar analyst Damien Conover said.

  • NEW YORK, April 14- After years of responding to shareholder calls for stock buybacks and dividends, major American companies are hearing a different demand from investors: buy growth.

  • Early movers: QCOR, SYMC, GM, UA & more Monday, 7 Apr 2014 | 7:48 AM ET
    Traders work on the floor of the New York Stock Exchange during early trading on December 16, 2013 in New York City.

    Some of the names on the move ahead of the open.

  • WASHINGTON, March 28- The U.S. Federal Trade Commission seeks a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired, an FTC official told a legal conference on Friday.

  • A string of mega deals drives global M&A recovery in Q1 Thursday, 27 Mar 2014 | 8:00 PM ET

    *Morgan Stanley tops global rankings. LONDON, March 28- A string of large transactions drove the value of global mergers and acquisitions activity up by 54 percent in the first quarter compared to the same period last year, reflecting greater deal-making confidence among chief executives.

  • In the short term, that is expected to benefit larger global competitors, such as Teva Pharmaceutical Industries Ltd, Actavis Plc and Mylan Inc, which will be called upon to supply drugs no longer available from some of their rivals in India, they said.

  • Feb 27- Valeant Pharmaceuticals International Inc sees close to 50 opportunities for mergers or acquisitions, its chief executive said on Thursday, as it aims to become one of the world's five biggest pharmaceutical companies.

  • NEW YORK, Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal payments business.

  • Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal division.

  • Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal division. Marc Andreessen and Scott Cook, both long-term eBay board members, bore the brunt of Icahn's conflict allegations.

  • Feb 18- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.

  • *Forest Labs shares soar; Actavis agrees to buy company. NEW YORK, Feb 18- The S&P 500 and Nasdaq rose on Tuesday, following Wall Street's biggest weekly gain of the year, as merger activity increased confidence that there is value in the stock market even as the benchmark index nears a record high.

  • *Forest Labs shares jump, Actavis to purchase. NEW YORK, Feb 18- U.S. stocks edged up on Tuesday, following Wall Street's biggest gain of the year, as merger activity boosted confidence there is still value in the market even as the S&P 500 nears a record high.